Patent · US Active

Method of treating triple negative breast cancer

US10736902B2 · kind B2 · utility

2Cited by

0References

21Claims

0Family size

Assignee

GEISTLICH PHARMA AG · CH

Inventors

H. Redmond · Cork, IE
Rolf W. Pfirrmann · Luzern, CH

Key dates

Filing date	Mar 17, 2017
Grant date	Aug 11, 2020
Priority date	—
Expiry date	Mar 17, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of treating a patient suffering from TNBC by a multidisciplinary method involving treating the patient with a plurality of the following treatments: i) one or more checkpoint inhibitors; ii) hyperthermia treatment; iii) low dose chemotherapy; iv) Interleukin-2 (IL-2); and v) a compound selected from the group consisting of taurolidine, taurultam, oxathiazin-like compounds, and combinations thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.